Findings

What do systematic reviews say?

5 questions · 7 findings · 2 reviews

No studies found 3 · 42.9%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 42.9%High 1 · 14.3%

Oxygen requirement at 36 weeks' postmenstrual age · preterm infants at risk for apnea

Methylxanthine probably leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.78 [0.63, 0.97]
3 studies · 541 participants
Moderate

Oxygen requirement at 36 weeks' postmenstrual age · preterm infants with apnea

Methylxanthine probably leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.72 [0.58, 0.89]
1 study · 805 participants
Moderate

Oxygen requirement at 36 weeks' postmenstrual age · preterm infants prior to extubation

Methylxanthine probably leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.81 [0.7, 0.92]
2 studies · 704 participants
Moderate

Oxygen requirement at 36 weeks' postmenstrual age · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Methylxanthine leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (high certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.77 [0.69, 0.85]
4 studies · 2142 participants
High

Chronic lung disease · treatment of apnea

The review found no eligible studies for this question.

3 findings from 1 review

Doxapram for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Doxapram for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Doxapram for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found